Kate Esselen, MD, MBA

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-4040


Kate Esselen, MD, MBA

Beth Israel Deaconess Medical Center


  • Assistant Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Gynecologic Oncologist, Obstetrics & Gynecology, Beth Israel Deaconess Medical Center


Research Abstract

I am a gynecologic oncologist at Beth Israel Deaconess Medical Center and an assistant professor in

Obstetrics, Gynecology and Reproductive Medicine Harvard Medical School in Boston, MA. I completed my

fellowship in Gynecologic Oncology in 2015 at Brigham and Women’s Hospital. I have also earned my Masters

in Business Administration (M.B.A.) in healthcare management. I am most interested in health outcomes in

gynecologic cancers, particularly patient-centered outcomes including financial hardship related to cancer care,

value-based healthcare utilization and healthcare disparities. I have authored ten original research reports and

co-authored many others. Several of these studies highlight my interest in examining the value of care in

gynecologic malignancies and its economic impact from a healthcare system perspective and others in

understanding the basic biology of gynecologic malignancies and associated gynecologic conditions such as


In my primary role as a clinician and surgeon, I have the privilege of caring for women at diagnosis and

following them closely for years afterwards in surveillance, recurrence and end-of-life care. My healthcare

management background also provides a unique opportunity to study the financial impact of cancer care in

patients with gynecologic malignancies. In addition to helping individual patients navigate their disease process

and the healthcare system, I aim to conduct research that will influence how other clinicians care for their

patients and improve how patients understand the financial impact of their disease. I intend to develop a career

as a clinical researcher that leverages my expertise in gynecologic oncology and my Masters in Business

Administration, to evaluate patient-centered outcomes in gynecologic cancers and develop meaningful

interventions with my translational collaborators to improve the value of care delivered to all patients.


Powered by Harvard Catalyst
  • Connor YD, Miao D, Lin DI, Hayne C, Howitt BE, Dalrymple JL, DeLeonardis KR, Hacker MR, Esselen KM, Shea M. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. Gynecol Oncol 2020. PubMed
  • Ore AS, Shear MA, Liu FW, Dalrymple JL, Awtrey CS, Garrett L, Stack-Dunnbier H, Hacker MR, Esselen KM. Adoption of enhanced recovery after laparotomy in gynecologic oncology. Int J Gynecol Cancer 2019. PubMed
  • Luckett R, Mogowa N, Li HJ, Erlinger A, Hacker MR, Esselen K, Feldman S, Shapiro R, Morroni C, Ramogola-Masire D. Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus. Obstet Gynecol 2019; 134:840-849. PubMed
  • Franconeri A, Boos J, Fang J, Shenoy-Bhangle A, Perillo M, Wei CJ, Garrett L, Esselen K, Fong L, Brook OR. Adnexal mass staging CT with a disease-specific structured report compared to simple structured report. Eur Radiol 2019; 29:4851-4860. PubMed
  • Bouberhan S, Shea M, Kennedy A, Erlinger A, Stack-Dunnbier H, Buss MK, Moss L, Nolan K, Awtrey C, Dalrymple JL, Garrett L, Liu FW, Hacker MR, Esselen KM. Financial toxicity in gynecologic oncology. Gynecol Oncol 2019; 154:8-12. PubMed
  • Lightfoot MDS, Esselen KM, Haviland MJ, Dalrymple JL, Awtrey CS, Garrett LA, Hacker MR, Liu FW. Participation in global health delivery: Survey results from the Society of Gynecologic Oncology. Gynecol Oncol Rep 2018; 26:7-10. PubMed
  • Luckett R, Kalenga K, Liu F, Esselen K, Awtrey C, Mmalane M, Moloi T, Ricciotti H, Grover S. Pilot of an International Collaboration to Build Capacity to Provide Gynecologic Oncology Surgery in Botswana. Int J Gynecol Cancer 2019; 28:1807-1811. PubMed
  • Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol 2016. PubMed
  • Esselen KM, Terry KL, Samuel A, Elias KM, Davis M, Welch WR, Muto MG, Ng SW, Berkowitz RS. Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery? Gynecol Oncol 2016. PubMed
  • Hinchcliff EM, Esselen KM, Watkins JC, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Quade BJ, Muto MG. The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma. J Minim Invasive Gynecol 2016. PubMed
  • Mahdi H, Gockley A, Esselen K, Marquard J, Nutter B, Yang B, Hinchcliff E, Horowitz N, Rose PG. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. Gynecol Oncol 2015; 139:407-12. PubMed
  • Esselen KM, Vitonis A, Einarsson J, Muto MG, Cohen S. Health Care Disparities in Hysterectomy for Gynecologic Cancers: Data From the 2012 National Inpatient Sample. Obstet Gynecol 2015; 126:1029-39. PubMed
  • Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY, Ducar MD, Thorner AR, MacConaill LE, Doran G, Pedamallu CS, Ojesina AI, Wong RR, Wang VW, Freeman SS, Lau TS, Kwong J, Chan LK, Fromer M, May T, Worley MJ, Esselen KM, Elias KM, Lawrence M, Getz G, Smith DI, Crum CP, Meyerson M, Berkowitz RS, Wong YF. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer 2015. PubMed
  • Strickland KC, Nucci MR, Esselen KM, Muto MG, Chopra S, George S, Howitt BE. Solitary Fibrous Tumor of the Uterus Presenting With Lung Metastases: A Case Report. Int J Gynecol Pathol 2015. PubMed
  • Rauh-Hain JA, Foley OW, Winograd D, Andrade C, Clark RM, Vargas RJ, Hinchcliff EM, Esselen KM, Horowitz NS, del Carmen MG. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol 2019; 212:600.e1-8. PubMed
  • Aviki EM, Esselen KM, Barcia SM, Nucci MR, Horowitz NS, Feltmate CM, Berkowitz RS, Orgill DG, Viswanathan AN, Muto MG. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol 2015; 137:60-5. PubMed
  • Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol 2014. PubMed
  • Esselen KM, Ng SK, Hua Y, White M, Jimenez CA, Welch WR, Drapkin R, Berkowitz RS, Ng SW. Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens. Gynecol Oncol 2014; 132:316-21. PubMed
  • Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23:1219-25. PubMed
  • Esselen KM, Feldman S. Cost-effectiveness of cervical cancer prevention. Clin Obstet Gynecol 2013; 56:55-64. PubMed
  • Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol 2012. PubMed
  • Esselen KM, Boruta DM, del Carmen M, Schorge JO, Goodman A, Growdon WB. Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review. Int J Gynecol Cancer 2011; 21:1078-83. PubMed
  • Vargas R, Barroilhet LM, Esselen K, Diver E, Bernstein M, Goldstein DP, Berkowitz RS. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2015; 59:188-94. PubMed